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Purpose: Matrix metalloproteinases (MMPs) are considered to play a central role in the
pathogenesis of abdominal aortic aneurysms (AAAs). Doxycycline (Dox) has direct
MMP-inhibiting properties in vitro, and it effectively suppresses the development of
elastase-induced AAAs in rodents. The purpose of this study was to determine if treat-
ment with Dox suppresses MMPs within human aneurysm tissue and to elucidate the
molecular mechanisms underlying this effect. 
Methods: Aneurysm tissues were obtained from 15 patients with an AAA, eight of whom
had been treated with Dox before surgery (100 mg orally twice a day for 7 days). Protein
extracts were examined by means of gelatin zymography and immunoblot analysis, and
RNA was examined by means of reverse transcription-polymerase chain reaction (RT-
PCR). The effects of Dox on MMP production were further examined in human THP-
1 mononuclear phagocytes in vitro.
Results: No detectable difference was found between groups by using substrate zymog-
raphy as a means of assessing total MMP activity, but Dox treatment was associated with
a slight (24.4%) reduction in the activated fraction of 72-kDa gelatinase (MMP-2; P <
.05). In contrast, a 2.5-fold reduction in the amount of extractable 92-kDa gelatinase
(MMP-9) protein in Dox-treated patients was revealed by means of immunoblot analy-
sis (P < .05). Also, a 5.5-fold (81.9%) reduction in MMP-9 messenger RNA (mRNA) in
Dox-treated patients was demonstrated by means of quantitative competitive RT-PCR
(mean ± SE, mol MMP-9/mol β-actin: 1.3 ± 0.5 vs 7.2 ± 3.1; P < .04). There was no
significant difference between groups in the relative expression of MMP-2 protein or
mRNA. In cultured THP-1 monocytes stimulated with phorbol ester, the expression of
MMP-9 protein and mRNA were both decreased after exposure to relevant concentra-
tions of Dox in vitro.
Conclusion: In addition to its recognized effects as a direct MMP antagonist, Dox may
influence connective tissue degradation within human aneurysm tissue by reducing
monocyte/macrophage expression of MMP-9 mRNA and by suppressing the post-trans-
lational processing (activation) of proMMP-2. Through this complementary combina-
tion of mechanisms, treatment with Dox may be a particularly effective strategy for
achieving MMP inhibition in patients with an AAA. (J Vasc Surg 2000;31:325-42.)
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Abdominal aortic aneurysms (AAAs) develop
through a complex degenerative process associated
with aging, atherosclerosis, and chronic inflamma-
tion.1-4 Through numerous studies conducted with-
in the last decade, a pathophysiologic concept has
emerged that proteolytic degradation of medial
elastin is responsible for weakening and dilatation of
the aortic wall and that collagen degradation is
responsible for aneurysm rupture.5-8 An abundant
amount of evidence suggests that these alterations
are mediated by members of the matrix metallopro-
teinase (MMP) family,3,9,10 including collagenase-1
(MMP-1), stromelysin-1 (MMP-3), the 72-kDa and
92-kDa gelatinases (MMP-2 and MMP-9, respec-
tively), and macrophage elastase (MMP-12).11-21
MMP-9 has attracted particular interest because it
has activity against insoluble elastin fibers22-24 and
because it is the most abundant elastolytic proteinase
produced by human AAA tissues in vitro.16 MMP-9
is also abundantly expressed in situ by aneurysm-
infiltrating macrophages located at the site of tissue
damage,16,18 is synthesized in AAA tissue in a man-
ner correlating with increased aneurysm diameter,25
and is elevated in the circulation of patients with an
AAA.26 By using an elastase-induced model of AAA,
we recently found that targeted gene deletion of
MMP-9 is sufficient to prevent experimental
aneurysmal degeneration in mice (Pyo et al, manu-
script submitted). These observations have fostered
the idea that MMP-9 and other metalloproteinases
might provide useful biological markers of aortic
aneurysm disease and potential targets for pharma-
cologic therapy in patients with a small asympto-
matic AAA.1-4
Consistent with the notion that inflammatory cell
production of elastolytic MMPs plays an important
role in aneurysmal degeneration, the development of
experimental AAAs has been shown to be suppressed
by leukocyte-depleting antibodies,27 glucocorti-
coids,28 nonsteroidal anti-inflammatory agents,29,30
and direct MMP antagonists.31-33 Doxycycline and
other tetracycline derivatives also inhibit the develop-
ment of elastase-induced aneurysmal degeneration in
the rat, in which they exhibit a greater therapeutic
efficacy than any other agent tested to date.34-36
Studies examining the effect of tetracyclines on
experimental AAAs were based on the recognition
that these compounds display pronounced MMP-
inhibiting properties, as first elucidated by Golub and
colleagues in experimental models of periodontal dis-
ease.37,38 Like naturally occurring tissue inhibitors of
metalloproteinases (TIMPs), tetracyclines are known
to exert direct inhibition of MMP activities, as
demonstrated by in vitro assays. Non-antibiotic
chemically modified tetracyclines have a similar effi-
cacy as MMP inhibitors, demonstrating that the
MMP-inhibiting properties of tetracyclines are unre-
lated to their antimicrobial effects.38-42 Because
tetracyclines are safe and effective at the dose sched-
ules typically used in clinical practice,43-46 they have
been successfully tested in several conditions associat-
ed with elevated MMP activity and connective tissue
destruction (eg, rheumatoid arthritis, osteoarthritis,
and periodontal disease).44,47,48 Although this indi-
cates that tetracyclines might have similar use as me-
talloproteinase inhibitors in patients with an AAA, it
is not yet known if these agents can effectively sup-
press MMPs in the complex tissue environment of
degenerative human aortic aneurysms.
It has recently become apparent that direct inhi-
bition of metalloproteinase activity, as measured by
means of in vitro assays, may be only one of several
mechanisms by which tetracycline derivatives pre-
vent MMP-mediated matrix degradation.42 For
example, it has been revealed by means of studies in
cell culture that tetracyclines can also suppress the
production of at least some MMPs, through mecha-
nisms involving selective downregulation of gene
transcription.49-52 Furthermore, the normal extra-
cellular processing associated with the activation of
proMMPs may be altered in the presence of doxycy-
cline, resulting in diminished activation, accelerated
enzyme degradation, and loss of enzymatic activi-
ty.53 These findings suggest a broad spectrum of
mechanisms by which tetracyclines might inhibit
MMP-mediated matrix degradation, including
direct inhibition of enzyme activity, suppression of
extracellular proenzyme activation, and downregula-
tion of messenger RNA (mRNA) synthesis. Which
of these mechanisms might be most important dur-
ing clinical use of tetracyclines remains unknown.
With a view toward the possibility that tetracy-
cline derivatives might be used to suppress the
degradation of aortic wall structural proteins in
patients with an AAA, we sought to determine
whether clinically applicable treatment with doxycy-
cline has an influence on the production of MMPs in
human aneurysm tissue. The results of this investi-
gation demonstrate that even short-term treatment
with doxycycline is associated with a significant
reduction in the expression of MMP-9 protein and
mRNA, both in human aneurysm tissues in vivo and
in a human monocytic cell line in culture. We also
found that treatment with doxycycline promotes a
reduction in the post-translational processing (acti-
vation) of proMMP-2 in the diseased aortic wall.
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These findings indicate that, through a combination
of favorable molecular mechanisms, treatment with
doxycycline may be a particularly effective strategy
for achieving MMP inhibition in patients with an
AAA.
MATERIALS AND METHODS
Patients, doxycycline treatment, and tissue
specimens. Eight patients scheduled for elective
repair of an infrarenal AAA were treated with doxy-
cycline. After providing informed written consent
according to a protocol approved by the Washington
University School of Medicine Human Research
Subjects Committee, each patient was provided with
a supply of 100 mg doxycycline hyclate capsules
(Danbury Pharmacal, Danbury, Conn). Doxycycline
was administered twice daily for at least 7 days
before surgery, including the morning of the
planned procedure. At the time of aneurysm repair,
a full-thickness specimen of aortic wall was obtained
from the point of maximal dilatation. Control AAA
tissues were obtained in a similar manner from seven
untreated patients undergoing elective aortic
aneurysm repair during the same period. Each aortic
tissue specimen was snap-frozen in liquid nitrogen
and stored at –80°C before protein and nucleic acid
extraction.
Substrate zymography. Protein extracts were
obtained from frozen aortic tissue samples as
described,21 by pulverizing under liquid nitrogen and
extracting in ice-cold 50 mmol/L Tris-HCl buffer,
with a pH of 7.5, containing 1.0 mol/L NaCl, 2.0
mol/L urea, 0.1% (w:v) Brij-35, 0.1% ethylenedi-
amine tetraacetate, and a mixture of serine, cysteine,
and aspartic protease inhibitors (Protease Inhibitor
Cocktail No. P8340; Sigma Chemical, St. Louis,
Mo). After centrifugation at 10,000g (1 hour at 4°C),
the supernatant was centrifugally concentrated by
using a 5,000 molecular weight cut-off membrane (2
hours at 4°C). Samples (10 µg total protein per lane)
were subjected to gelatin zymography under non-
denaturing conditions, as described.16 After staining
gels with 0.5% Coomassie Blue R-250 in 40%
methanol/10% acetic acid (Sigma Chemical), gelatin-
degrading activities were observed as clear bands
against a dark background of intact substrate. The rel-
ative molecular weight of each proteolytic band was
determined by comparison with the migration of
authentic human MMP-9 and MMP-2 and molecular
weight standards (Bio-Rad, Hercules, Calif). Gels
were dried, scanned, and analyzed by means of inverse
densitometry. The relative proportion of each enzyme
present in the active form was calculated from densi-
tometric measurements as a fraction of the total
amount of activity present for that enzyme.
Immunoblot analysis. Aortic extract samples
were normalized to total protein (100 µg per lane)
and resolved by sodium dodecylsulfate-polyacry-
lamide gel electrophoresis (SDS-PAGE) under
reducing conditions, by using 12% polyacrylamide
gels. Proteins were transferred to polyvinylidene
difluoride membranes (Bio-Rad), blocked with 
5% powdered milk in 20 mmol/L Tris HCl, 
pH 7.5, 0.5 mol/L NaCl, 0.1% Tween-20, and incu-
bated overnight at 4°C with monoclonal antibodies
to MMP-9 or MMP-2 (Research Diagnostics,
Flanders, NJ). Peroxidase-conjugated goat anti-
mouse IgG (Jackson Immunoresearch Laboratories,
West Grove, Pa) was used as the secondary antibody,
and immune complexes were visualized by means of
enhanced chemiluminescence (ECL) with kit reagents
(Amersham Life Science, Arlington Heights, Ill). The
relative density of immunoreactive MMP-2 or MMP-
9 was determined for each sample, and the amount of
each MMP recovered in tissue extracts from the doxy-
cycline-treated and untreated groups was recorded as
the mean plus or minus SEM.
Reverse transcription-polymerase chain reac-
tion and Southern blot analysis. Aortic tissue
samples were pulverized under liquid nitrogen, and
total RNA was isolated by means of guanidium 
iso-thiocyanate-phenol-chloroform extraction with
Trizol reagent (Gibco BRL, Grand Island, NY), as
described.21 The integrity of the RNA from each
sample was verified by means of agarose gel elec-
trophoresis. All samples were normalized to the same
amount of total RNA, and each sample was analyzed
in duplicate, along with control samples for genomic
DNA (absence of reverse transcriptase) and nonspe-
cific DNA contamination (absence of RNA tem-
plate). Reactions were performed on a Gene AMP
2400 PCR thermal cycler system from Perkin-Elmer
(Norwalk, Conn). First strand complementary DNA
(cDNA) synthesis was performed in a total reaction
volume of 20 µL using 0.5 µg of total RNA, 20 units
RNase inhibitor, 2.5 µmol/L random hexamers, 1
mmol/L dNTPs, and 50 units murine Moloney
leukemia virus reverse transcriptase, as provided in
the GeneAmp RNA polymerase chain reaction
(PCR) kit from Perkin-Elmer/Roche Molecular
Systems (Branchburg, NJ). Samples were incubated
at 42°C for 15 minutes before terminating the reac-
tion by heating to 99°C for 5 minutes, then cooling
to 5°C. Reverse transcription products served as the
template for PCR amplification, using primer pairs
specific for human MMP-2, MMP-9, and β-actin
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(Table I). PCR amplifications were performed in a
100 µL reaction volume with 10 mmol/L Tris-HCl
buffer containing 50 mmol/L KCl, 2 mmol/L
MgCl2, 100 pmol (each) forward and reverse com-
plement primers, and 2.5 units of AmpliTaq DNA
polymerase. Reactions included 4 minutes at 95°C
for denaturation and 30 cycles of 1 minute at 95°C,
1 minute at 55°C, and 1 minute at 72°C; samples
were then incubated for 7 minutes at 72°C for final
extension before holding at 4°C. A 30 µL aliquot of
each sample was resolved by 1.5% agarose elec-
trophoresis in the presence of 5 ng/mL ethidium
bromide, and DNA was visualized under ultraviolet
light to detect the presence of PCR amplification
products at the anticipated size (Table I).
Reverse transcription-polymerase chain reaction
(RT-PCR) products were transferred by means of
standard Southern techniques to Hybond N+ nylon
membranes (Amersham Life Science). Hybridization
was performed with cDNA oligonucleotide probes
specific for MMP-9, MMP-2, or β-actin (Table I),
by using an ECL 3’-oligolabeling and detection sys-
tem (Amersham). After prehybridization, mem-
branes were incubated at 42°C for 90 minutes with
10 ng/mL labeled cDNA. Membranes were washed
under stringent conditions, incubated with horse-
radish peroxidase-conjugated anti-fluorescein anti-
bodies followed by ECL detection reagents, and
exposed to radiographic film. For semiquantitative
analysis, the relative density of each MMP band was
compared with that obtained for β-actin from the
same sample, and each experiment was conducted at
least twice for each RNA sample. The mean plus or
minus SEM of relative density ratios was determined
for all samples from each experimental group.
Competitive reverse transcription-polymerase
chain reaction analysis. When sufficient RNA was
available, competitive RT-PCR was also used for
more accurate quantification of MMP-9 mRNA lev-
els in aortic tissue specimens.54 The MMP-9 com-
petitor (347 base pair [bp]) was constructed from
full-length human MMP-9 cDNA by means of a
modification of methods described by Celi et al,55
then subcloned into pGEM-T Easy (Promega,
Madison, Wis) and verified by means of direct
sequencing (ABI PRISM Model 377; Perkin-
Elmer/Roche Molecular Systems). When amplified
in parallel with the same primer pairs used for MMP-
9, the competitor cDNA produced a product that
differed in size by 104 bp from the native cDNA
product. A competitor constructed for human β-
actin produced a PCR product 80 bp shorter than
that obtained from the native β-actin cDNA.
After RT, competitive PCR reactions for MMP-9
and β-actin were performed in total reaction volumes
of 20 µL containing 50 mmol/L KCl, 4 mmol/L
MgCl2, 0.4 mmol/L dNTP, 2.5 units of AmpliTaq
DNA polymerase, and 100 pmol (each) forward and
reverse primers. Each reaction contained a known
quantity of the competitor cDNA in a series of at least
four different concentrations for each specimen exam-
ined. PCR products were separated on 1.5% agarose
containing ethidium bromide and photographed
under ultraviolet light. Photographs were scanned,
and the band densities corresponding to the amplified
native cDNA and the competitor cDNA were calcu-
lated as described. After adjusting densitometric mea-
surements for the different size of the two products,
the log ratio of the band densities was plotted against
the log concentration of competitor added (in atto-
moles DNA). The x-intercept was interpolated from
the calculated trend line to identify the point at which
the concentrations of the two products were equal.
The quantity of MMP-9 cDNA present in each sam-
ple was normalized to β-actin and expressed as a
molar ratio for statistical analysis.
Effects of doxycycline on phorbol-stimulated
human THP-1 monocytes. Human THP-1 mononu-
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Table I. Oligonucleotides used in reverse transcription-polymerase chain reaction and Southern blot analysis
Human MMP-2, GenBank accession no. J03210 (anticipated product, 385 bp)
Forward primer: 5’-GAGTACTGCAAGTTCCCCTT-3’ (bp 644–663)
Reverse complement: 5’-TGTTGCCCAGGAAAGTGAAG-3’ (bp 1009–1028)
Complementary DNA probe: 5’-GGCACATCCTATGACAGCTG-3’ (bp 848–867)
Human MMP-9, GenBank accession no. J05070 (anticipated product, 401 bp)
Forward primer: 5’-AATCTCACCGACAGGCAGCT-3’ (bp 131–150)
Reverse complement: 5’-CCAAACTGGATGACGATGTC-3’ (bp 512–531)
Complementary DNA probe: 5’-GGCAGATTCCAAACCCTTTGA-3’ (bp 332–351)
Human β-actin, GenBank accession no. X00351 (anticipated product, 195 bp)
Forward primer: 5’-ATCGTGCGTGACATTAAGG-3’ (bp 632–650)
Reverse complement: 5’-ACAGGACTCCATGCCCAGG-3’ (bp 808–826)
Complementary DNA probe: 5’-CTGGACTTCGAGCAGGAGAT-3’ (bp 671–690)
bp, Base pair.
clear phagocytes were obtained from the American
Type Culture Collection (ATCC; Rockville, Md) and
maintained in RPMI-1640 (Gibco BRL) supplement-
ed with 10% fetal calf serum, 10 mmol/L HEPES,
and penicillin/streptomycin. Cells were grown in sus-
pension culture at 37°C in a humidified 5% CO2
atmosphere, then harvested by centrifugation and
resuspended at 5 × 105 cells per mL in RPMI-1640
supplemented with 2.5% fetal calf serum and varying
concentrations of doxycycline HCl (Sigma Chemical).
After 24 hours, cells were harvested by means of cen-
trifugation and resuspended in media containing the
same concentration of doxycycline and 100 nmol/L
phorbol 12-myristate 13-acetate (PMA; Sigma). After
an additional 48 hours to allow PMA-induced differ-
entiation, conditioned medium was collected and
mixed with 0.1% ethylenediamine tetraacetate (to pre-
vent proMMP auto-activation), then stored at –70°C.
Adherent THP-1 cells were lysed in RNA extraction
buffer, and total RNA was isolated, as described,
before RT-PCR analysis.
Statistical analysis. All blots were processed with
a PhotoSmart image scanner (Hewlett-Packard, Palo
Alto, Calif) and examined with Phoretix 1D Quantifier
version 4.01 densitometry software from NonLinear
Dynamics (Newcastle upon Tyne, UK). Data are pre-
sented as the mean plus or minus SEM, and all statis-
tical calculations were performed by using SAS for
Windows (SAS Institute, Cary, NC), with the level of
significance set at 0.05. For comparisons between the
doxycycline-treated and the untreated control groups,
continuous data were compared by using the Student
t test, assuming equal variances. Logarithmic transfor-
mation was used as necessary to normalize the data
distribution. Categorical data were analyzed with the
χ2 test. For the cell culture experiments, correlations
between doxycycline concentrations and the measured
levels of MMP-9 mRNA (or protein) were calculated
by using Pearson correlation coefficients (r).
RESULTS
Patient characteristics and doxycycline treat-
ment. No significant differences existed between
the two groups of patients in age or aneurysm size
(Table II). All eight patients treated with doxycy-
cline were compliant by self-report, and no patient
described adverse effects associated with drug treat-
ment. No patient had to decrease the dose of doxy-
cycline or discontinue drug treatment during the 1-
week period of study.
Substrate zymography. Gelatin substrate zy-
mography was initially used as a means of detecting
the presence of enzymatically active MMP-9 and
MMP-2 in AAA tissue extracts. As shown by the rep-
resentative zymogram in Fig 1A, all aneurysm spec-
imens contained gelatinolytic activities correspond-
ing to proMMP-9 (92 kDa), active MMP-9 (88
kDa), proMMP-2 (72 kDa), and active MMP-2 (68
kDa). In four separate experiments, no differences
were discernable between patients treated with
doxycycline and untreated control patients in the
total amount of activity attributable to either MMP-
9 or MMP-2. By using inverse densitometry to esti-
mate the fraction of each enzyme present in the
active versus latent forms, we detected no difference
in the fractional activation of MMP-9. By means of
the same analysis, we found that doxycycline treat-
ment was associated with a slight but significant
reduction in the activated fraction of MMP-2
(untreated controls, 46.0% ± 3.7% of total MMP-2
activity; doxycycline-treated, 33.9% ± 3.6% of total
MMP-2 activity; P < .05).
Effects of doxycycline on matrix metallopro-
teinase protein expression in abdominal aortic
aneurysm tissue. Given the variables inherent in
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Table II. Clinical characteristics of the patient
population
Untreated control patients (n = 7)
Patient number Sex Age (years) AAA (cm)*
1 M 74 4.9
2 M 75 5.9
3 F 76 3.0
4 M 65 9.5
5 M 66 7.0
6 M 85 9.0
7 M 70 8.0
Mean ± SE 6 M, 1 F 73.6 ± 2.6 6.76 ± 0.88
Patients treated with doxycycline (n = 8)
Patient number Sex Age (years) AAA (cm)
8 M 75 5.0
9 F 69 5.0
10 M 72 5.5
11 M 73 5.0
12 F 79 6.5
13 F 59 4.6
14 M 81 8.0
15 M 67 4.2
Mean ± SE 5 M, 3 F 72.4 ± 2.5 5.48 ± 0.43
*Preoperative measurements of AAA size were obtained by means
of computed tomography. There were no significant differences
between the untreated control group and the doxycycline-treated
group in age or AAA size. 
AAA, Abdominal aortic aneurysm; M, male; F, female.
substrate zymography, immunoblotting of AAA
extracts was used as a means of quantifying the
effects of doxycycline on aortic wall MMP produc-
tion. Samples were processed in the presence of pro-
teinase inhibitors to prevent autocatalytic processing
during extraction, and the gels were run with an
equal amount of total protein in each lane.
Immunoblots were performed under denaturing
conditions by using a monoclonal antibody to
human MMP-9 and polyclonal antibodies to MMP-
2. Immunoreactive MMP-9 was consistently detect-
ed in aneurysm tissue from untreated control
patients, but not in healthy aortic tissue (Fig 2A).
However, aneurysm extracts from patients treated
with doxycycline contained appreciably less im-
munoreactive MMP-9 than those from untreated
control patients. When evaluated by means of den-
sitometry (Fig 2B), the level of total extractable
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Fig 1. Substrate zymography. Total protein was extracted from the aneurysm wall tissue of
patients treated with doxycycline (n = 5), untreated control patients (n = 5), and two healthy
aortas. Equivalent amounts of protein (10 ug per lane) were electrophoretically separated on
a 10% polyacrylamide gel containing 1 mg/mL gelatin. A, Gelatinase activity was identified by
clear bands on a dark background after staining with Coomassie Blue (representative of four
separate experiments). B, The mean density of bands corresponding to proMMP-9 (92 kDa),
active MMP-9 (88 kDa), proMMP-2 (72 kDa), and active MMP-2 (68 kDa) were measured.
There was no difference between groups in total matrix metalloproteinase activity for either
MMP-2 or MMP-9 (not shown). The activated fraction of MMP-2 was slightly decreased in
samples from patients with abdominal aortic aneurysms treated with doxycycline, compared
with those from untreated control patients (P < .05), but there was no difference in the acti-
vated fraction of MMP-9. NS, not significant.
A
B
MMP-9, as measured in arbitrary density units
(ADU), was significantly higher in the untreated
aneurysm control group than in both aortas of
patients treated with doxycycline (P < .05) and
healthy aortas (P < 0.02; untreated AAAs, 32.1 ±
5.85 ADU; doxycycline-treated AAAs, 12.9 ± 5.93
ADU; healthy aortas, 1.87 ± 0.59 ADU). Indeed,
the difference in MMP-9 between aortas of patients
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Fig 2. Immunoblotting for MMP-9 in human aortic tissue extracts. Total protein was extracted
from the aortic wall tissue of patients treated with doxycycline (n = 6), untreated control patients
(n = 4), and two healthy aortas. Equivalent amounts of protein (100 ug per lane) were separat-
ed by sodium dodecylsulfate-polyacrylamide gel electrophoresis and transferred to polyvinylidene
difluoride membranes. A, Blots incubated with a monoclonal antibody to human MMP-9
demonstrated a single band migrating at 92 kDa. B, By using band densitometry, samples from
untreated patients with abdominal aortic aneurysms contained significantly more MMP-9 pro-
tein than those from healthy aortas (P < .05). Samples from patients with an abdominal aortic
aneurysm treated with doxycycline exhibited a significant decrease in the amount of detectable
MMP-9 protein, compared with those from untreated patients with an abdominal aortic
aneurysm (P < .05). There was no significant difference between the amount of MMP-9 in sam-
ples from the doxycycline-treated group and those from normal aortas. NS, not significant.
A
B
treated with doxycycline and healthy aortas was not
statistically significant. Also, the one specimen in the
doxycycline-treated group containing a substantial
amount of MMP-9 was obtained from the largest
aneurysm in the series (8.0 cm in diameter). In con-
trast to the results obtained for MMP-9, no signifi-
cant difference in the amount of this enzyme
extracted from AAA tissues in the doxycycline-treat-
ed group and the untreated control group was
revealed by means of immunoblot analysis of MMP-
2 (data not shown).
Treatment with doxycycline is associated with
a reduction in MMP-9 messenger RNA. The
observed reduction in extractable MMP-9 protein in
patients treated with doxycycline was somewhat sur-
prising, because of the abundant expression of this
proteinase in AAA tissue and the relatively short
period of doxycycline treatment. To clarify whether
this effect was caused by a concomitant reduction in
MMP-9 gene expression, we used RT-PCR to exam-
ine the effects of treatment with doxycycline on aor-
tic wall expression of MMP-9 and MMP-2.
With Southern hybridization of cDNA products
amplified from AAA tissue-derived RNA, bands cor-
responding to both MMP-9 and MMP-2 mRNA
were identified in all samples (Fig 3A). After densi-
tometric measurements and normalizing the samples
to β-actin mRNA as a constitutively expressed con-
trol, a significant reduction in aneurysm tissue
expression of MMP-9 between patients treated with
doxycycline and untreated control patients, but no
difference in MMP-2, was revealed by means of semi-
quantitative analysis (Fig 3B). Thus, the mean β-actin
normalized value of MMP-9 in aneurysm tissue from
the eight patients treated with doxycycline was 2.98
± 0.90 arbitrary relative density units (ARDU), a
value less than half of that observed in aneurysm tis-
sues from untreated control patients (6.02 ± 1.18
ARDU; P < .05, Student t test). In examining data
from individual patients, we noted that five of seven
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Fig 3. Reverse transcription-polymerase chain reaction and Southern blot analysis of MMP-9
and MMP-2 RNA in human aneurysm tissue. Total RNA was extracted from aneurysm wall tis-
sue of patients treated with doxycycline and untreated control patients, then amplified by reverse
transcription-polymerase chain reaction using primer pairs specific for MMP-9, MMP-2, and β-
actin. A, Reverse transcription-polymerase chain reaction products were confirmed by means of
Southern blot with specific probes within the amplified sequence. Although there was some vari-
ation in MMP-9 and MMP-2 production between specimens, there was a recognizable decrease
in the expression of MMP-9 between samples from patients treated with doxycycline and
untreated control patients. B, Densitometric analysis of MMP-9 and MMP-2 relative to β-actin.
There was a significant decrease in the amount of MMP-9 messenger RNA in samples from the
doxycycline-treated group, compared with untreated controls (P < .05). The difference between
groups for MMP-2 messenger RNA was not significant. NS, not significant. 
A B
specimens from those patients in the untreated con-
trol group had β-actin normalized MMP-9 values of
7 ARDU or more, whereas none of the eight speci-
mens from patients treated with doxycycline exhibit-
ed a relative density greater than 6.25 ARDU (Fig
4A). With the empirically-defined threshold of 7
ARDU to compare individual samples, a significantly
greater number of patients treated with doxycycline
had low levels of MMP-9 expression, compared with
untreated control patients (P < .01 by means of χ2
analysis). On the other hand, there were no apparent
differences in the relative levels of MMP-2 expression
between individual patients in the doxycycline-treat-
ed and untreated control groups (Fig 4B).
To quantify the results of RT-PCR analysis for
MMP-9 with more accuracy, we developed competi-
tor cDNA constructs for both human MMP-9 and
β-actin.19,25,54,55 By using the same primer pairs for
MMP-9, competitive PCR reactions resulted in two
amplification products readily distinguishable by size
on agarose gels (competitor cDNA, 347 bp; native
cDNA, 243 bp). Reactions performed in the pres-
ence of increasing concentrations of the competitor
resulted in a progressively diminished amount of the
JOURNAL OF VASCULAR SURGERY
Volume 31, Number 2 Curci et al 333
Fig 3. Cont’d. C, Densitometric measurements of MMP-9 messenger RNA for individual spec-
imens shown in A. Five of the seven specimens from untreated patients with abdominal aortic
aneurysms had normalized densities greater than or equal to 7 (horizontal line), whereas none of
the eight specimens from patients treated with doxycycline had normalized densities greater than
this value (P < .01; χ2 analysis). D, Densitometric measurements of MMP-2 messenger RNA for
the same samples shown in C. There was no detectable trend differentiating the two groups.
C
D
native cDNA product (Fig 5A). Densitometric data
were then used as a means of constructing a plot of
the known competitor concentration to the ratio of
the two cDNA products on a log-log scale, and lin-
ear regression was performed as a means of identify-
ing the point of equivalence at the x-intercept (ie,
corresponding to the amount of native cDNA pre-
sent in the original sample; Fig 5B). The amount of
MMP-9 mRNA present in each sample was then
normalized to the amount of β-actin measured in a
parallel series of competitive reactions.
Fig 6 summarizes the results of competitive RT-
PCR analysis for MMP-9 (expressed in mol MMP-
9/mol β-actin) in AAA specimens from five patients
treated with doxycycline and four untreated control
patients. The mean concentration of MMP-9 mRNA
in the doxycycline-treated group was 1.3 ± 0.5
mol/mol β-actin, compared with 7.2 ± 3.1 mol/mol
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Fig 4. Representative results of competitive reverse transcription-polymerase chain reaction
analysis for MMP-9. Native complementary DNA prepared by reverse transcription from AAA
tissue was amplified in a series of reactions containing increasing amounts of an MMP-9 com-
petitor complementary DNA, which competes with the native complementary DNA for a fixed
quantity of oligonucleotide primers. A, By design, the two products of polymerase chain reac-
tion amplification (at least 100 base pair different) can be distinguished by size after agarose
electrophoresis. B, The amount of competitor added (in moles) was plotted against the densi-
ty ratio of the two bands by using a log/log scale. After linear regression to ensure a correla-
tion coefficient less than –0.90, the x-intercept of the plotted data was determined to be the
point at which the (known) amount of competitor and the (unknown) amount of native com-
plementary DNA are equivalent. For accurate comparisons, the amount of MMP-9 comple-
mentary DNA in each sample was normalized to the amount of β-actin measured in a parallel
series of competitive reactions, and expressed as an mol/mol ratio.
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β-actin in the untreated control group (P < 0.04,
Student t test). Thus, treatment with doxycycline was
associated with a 5.5-fold (81.9%) reduction in the
relative expression of MMP-9 in aneurysm tissue,
even after only 1 week of therapy.
Doxycycline suppresses PMA-stimulated
MMP-9 expression in cultured human THP-1
mononuclear phagocytes. Because treatment with
doxycycline was associated with a reduction in aortic
wall expression of MMP-9 protein and mRNA, and
because mononuclear phagocytes are the principal
source of MMP-9 in human AAA tissue,16 we used a
human monocytic cell line to further examine the
regulation of MMP-9 expression by doxycycline in
vitro. THP-1 cells were preconditioned with doxycy-
cline for 24 hours at 0, 2.5, 5, 10, and 12 µmol/L, a
range of concentrations corresponding to tissue drug
levels measured during therapy.46,56,57 In the contin-
uing presence of doxycycline, the cells were then
exposed to 100 nmol/L PMA, an agent known to
stimulate MMP-9 production in mononuclear
phagocytes.58-60 At all concentrations of doxycycline
tested, THP-1 cells exhibited a normal morpholog-
ic appearance after PMA stimulation, with differen-
tiation to an adherent phenotype and cell spreading
on the substratum (data not shown). Suppression of
PMA-stimulated MMP-9 mRNA expression (nor-
malized to β-actin) was demonstrated by means of
RT-PCR analysis at doxycycline concentrations as
low as 5 µmol/L (Fig 6A). This effect was signifi-
cant and dose-dependent, with a Pearson correlation
coefficient of r = –0.88 (P < .05). Conditioned
media from these experiments were also examined
by means of Western blot to detect MMP-9 protein.
As in previous studies, four immunoreactive bands
were detected, which correspond to the proenzyme
and active forms of MMP-9, both free and com-
plexed to TIMP-1 (data not shown).16 By using the
sum of all four bands to calculate the total amount
of MMP-9 present, Fig 6B shows that there was also
a concentration-dependent decrease in the overall
amount of MMP-9 produced by cells exposed to
doxycycline (r = –0.90; P < .04). A similar effect of
doxycycline on the amount of enzymatically active
(88 kDa) MMP-9 present in the conditioned medi-
um (r = –0.95; P < .02) was revealed by means of
gelatin zymography (Fig 6C).
DISCUSSION
The present investigations were undertaken with
the view that doxycycline may eventually be useful as
an MMP inhibitor in the pharmacologic treatment
of patients with a small asymptomatic AAA. This
notion follows previous studies emphasizing the crit-
ical role of connective tissue degradation in aneurys-
mal degeneration, the demonstration that human
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Fig 5. Summary of competitive reverse transcription-polymerase chain reaction analysis for
MMP-9 in abdominal aortic aneurysm tissue. MMP-9 messenger RNA in aneurysm tissue was
quantified by means of competitive reverse transcription-polymerase chain reaction as shown
in Fig 4, by using total RNA obtained from five patients treated with doxycycline and four
untreated control patients. Data were expressed as a molar ratio of MMP-9 to β-actin.
Treatment with doxycycline was associated with a 5.5-fold (81.9%) reduction in the expression
of MMP-9, compared with the untreated control group (P < .04; Student t test).
and experimental AAAs are associated with chronic
inflammation and increased local production of
MMPs, and the recognition that tetracycline deriva-
tives have efficacy as MMP inhibitors, both in vitro
and in vivo. It has also been demonstrated that
doxycycline has beneficial effects in experimental
models of AAA, acting to suppress aortic wall elastin
degradation, MMP activity, and aneurysmal dilata-
tion.34-36,61 The background, rational, and current
strategies being used to develop pharmacological
approaches for patients with a small asymptomatic
AAA have recently been reviewed.1-4,61-63
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Fig 6. Effect of doxycycline on MMP-9 production in phorbol 12-myristate 13-acetate (PMA)-
stimulated THP-1 cells. An equivalent number of human THP-1 mononuclear phagocytes were
preincubated with either 0, 2.5, 5, 10, or 12 µmol/L doxycycline for 24 hours, then stimulated
for 48 hours with 100 nmol/L PMA in the continuing presence of doxycycline. At all concen-
trations of doxycycline tested, cells exhibited a normal morphologic appearance following PMA
stimulation with differentiation to an adherent phenotype (not shown). A, Cellular expression of
MMP-9 and β-actin messenger RNA was measured by means of reverse transcription-polymerase
chain reaction, with data normalized to β-actin and expressed as a percentage of control (cells not
exposed to doxycycline). Doxycycline induced a concentration-dependent inhibition of MMP-9
messenger RNA expression (r = –0.88; P < .05). B, Conditioned media were normalized to total
protein concentration and examined by means of Western blot with monoclonal antibodies to
human MMP-9. Total immunoreactive MMP-9 was measured by means of densitometry and
expressed as a percentage of control. Doxycycline induced a concentration-dependent decrease
in the amount of MMP-9 protein secreted into the conditioned medium (r = –0.90; P < .04). C,
Equal amounts of conditioned media were examined by means of gelatin zymography. Total
gelatinolytic activity attributable to MMP-9 was measured by means of inverse densitometry and
expressed as a percentage of control. Doxycycline (not present in the substrate buffer during
zymography) induced a concentration-dependent decrease in MMP-9 activity secreted into the
conditioned medium (r = –0.95; P < .02).
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The results presented here provide important
new information from a number of different perspec-
tives. First, we provide experimental evidence that
treatment with doxycycline can influence aortic wall
expression and activity of MMPs in patients with an
AAA. Previous studies have suggested that tetracy-
clines can localize to atherosclerotic plaques64,65 and
that tetracycline rapidly penetrates into the aneurys-
mal aorta after intravenous injection,66 but it has not
been previously demonstrated that doxycycline can
effectively inhibit MMPs in the complex tissue envi-
ronment of human AAAs. Our observations also
indicate that these effects can be achieved by means
of relatively short-term treatment with doxycycline at
clinically accepted doses, analogous to those used in
long-term antimicrobial therapy and other condi-
tions in which doxycycline has been used as an MMP
inhibitor (eg, periodontitis and rheumatoid arthri-
tis).46 Doxycycline was well tolerated in our patient
population, and no patient had adverse effects that
required discontinuation of the medication. This
provides a useful guideline for further studies of
doxycycline in patients with an AAA, both to deter-
mine whether similar effects on MMP production
can be achieved with lower dose schedules (eg, 20
mg orally twice a day),40,47,67 or eventually, whether
sustained treatment has an influence on the expan-
sion of small asymptomatic AAAs.63
Second, this study shows that, in addition to its rec-
ognized effects as a direct MMP antagonist, the mech-
anisms of action by which doxycycline might suppress
connective tissue degradation include substantial effects
on MMP gene expression (ie, MMP-9) and extracellu-
lar activation (ie, MMP-2). Through this complemen-
tary combination of mechanisms, treatment with doxy-
cycline would be expected to be particularly effective in
influencing aortic wall MMP activities in vivo.
Doxycycline and other tetracyclines are relatively non-
selective in their direct inhibition of various MMPs,
whereas their concomitant effects on MMP production
and activation appear to be potentially more selective.
In this study, we examined two metalloproteinases with
elastolytic activity, MMP-9 and MMP-2, both of which
are implicated in the pathophysiology of aneurysmal
degeneration.10 Selective inhibition of MMP-9 gene
expression in mononuclear phagocytes may be particu-
larly advantageous, because production of this enzyme
is elevated 10-fold in human AAA tissue.16,18-20,25,26
Although this may be another advantage of doxycycline
over more specific MMP antagonists, further studies
are underway to elucidate whether doxycycline influ-
ences the expression of other MMPs involved in pro-
gressive aneurysmal degeneration, such as interstitial
collagenases (MMP-1, MMP-8, and MMP-13),
stromelysin (MMP-3), and macrophage metalloelastase
(MMP-12).
In contrast to doxycycline’s effects on MMP-9,
we did not observe an effect of doxycycline on aor-
tic wall expression of MMP-2. A slight reduction in
the activated fraction of MMP-2 in extracts of AAA
tissue from patients treated with doxycycline was
revealed by means of semiquantitative analysis of
substrate zymograms; this may be at least partially
explained by proMMP-2 undergoing a unique pat-
tern of extracellular activation dependent on cell sur-
face binding, interactions with TIMP-2, and pro-
cessing by membrane-type metalloproteinases (MT-
MMPs).68-70 As nonselective antagonists of MMP
activity, doxycycline and other tetracyclines might be
expected to inhibit proMMP-2 activation by sup-
pressing MT-MMP activity. Inhibition of pericellular
proteolysis through this mechanism may be an
important pathway for the capacity of tetracycline
derivatives to suppress matrix degradation in a vari-
ety of clinical circumstances. In contrast, the activa-
tion of MMP-9 is thought to involve more diverse
pathways, involving other MMPs, oxidative process-
es, and serine proteases such as plasmin and uroki-
nase-type plasminogen activator.
A third observation from this study is that doxycy-
cline reduces the expression of MMP-9 in phorbol-
stimulated human THP-1 mononuclear phagocytes in
culture. The possibility that tetracyclines can regulate
MMP expression is supported by previous studies in
cultured cells, as demonstrated for MMP-2 in skin ker-
atinocytes,49 MMP-8 in rheumatoid synovial fibro-
blasts and endothelial cells,50 and MMP-9 in human
umbilical vein endothelial cells.51 In pathologic chon-
drocytes isolated from osteoarthritic joints, Shlopov et
al have also demonstrated that doxycycline induces a
downregulation in steady-sate mRNA for all three
mammalian collagenases (ie, MMP-1, MMP-8, and
MMP-13).52 Although we have observed indirect evi-
dence for a decrease in macrophage MMP-9 produc-
tion after treatment with doxycycline in the elastase-
induced rat model of AAA,34 the in vitro experiments
described here provide the first direct evidence for an
inhibitory effect of tetracyclines on MMP-9 expression
in mononuclear phagocytes. Monocyte-derived tissue
macrophages are the principal source of MMP-9 in
human and experimental aneurysm tissues and other
disorders characterized by chronic inflammation and
connective tissue destruction. Also, stimulation by
phorbol ester reflects one of the dominant molecular
pathways acting to induce MMP-9 transcription in
monocytic cells (ie, activation of protein kinase C and
JOURNAL OF VASCULAR SURGERY
Volume 31, Number 2 Curci et al 337
increased promoter activity regulated by activator pro-
tein-1 complexes).71 Thus, the demonstration that
doxycycline suppresses phorbol-stimulated expression
of MMP-9 in THP-1 cells, particularly at concentra-
tions typically achieved in tissue during systemic antibi-
otic treatment (4 to 20 µmol/L),46,56,57 supports the
likelihood that this is one of the mechanisms by which
doxycycline regulates MMP-9 expression in human
AAAs in vivo. Experiments in progress will help deter-
mine whether the molecular mechanisms of this effect
reside in a suppression of MMP-9 transcription or
mRNA stability, whether this mode of regulation
involves alterations in specific signal transduction path-
ways or transcriptional elements, and how doxycycline
influences other metalloproteinases and inhibitors nor-
mally expressed by mononuclear phagocytes.
There were a number of limitations inherent to
this study. For example, the study design was neces-
sarily correlative in nature, because we were only
able to evaluate the effects of systemic doxycycline
treatment by comparing measures of MMP produc-
tion in tissues obtained from two concurrent groups
of patients. Although these patients were not for-
mally randomized to treatment with doxycycline or
a placebo, the patients in each group were studied
during the same period, and they were not selected
by any specific criteria other than the contingencies
of preoperative scheduling. The two patient groups
were also found to be comparable in age and mean
aneurysm size. McMillan et al reported a correlation
between aortic wall MMP-9 mRNA expression and
aneurysm size, at least in small and medium AAAs
(5.0 to 6.9 cm in diameter).25 They also found that
MMP-9 expression is decreased in large aortic
aneurysms (larger than 7.0 cm in diameter).25 In
examining the individual patients in our study, we
found four AAAs larger than 7.0 cm in diameter in
the untreated control group, but only one in the
doxycycline-treated group. By using the correlations
drawn by McMillan et al, if there were any bias
introduced by discrepancies in the size of individual
aneurysms, we would have expected it to cause a
lower level of MMP-9 expression in the untreated
control group. Our results pointed to an effect in
the opposite direction, substantiating the conclusion
that treatment with doxycycline reduces AAA wall
expression of MMP-9. Because our results may still
have been biased by unmeasured differences
between the two groups in other clinical characteris-
tics, further studies are recommended to confirm
these findings.
A second limitation in design was that this study
involved only short-term treatment with doxycycline
in a relatively small number of patients. Although
this was imposed by practical concerns in treating
patients scheduled for elective AAA repair, it would
be interesting to evaluate how more sustained treat-
ment with doxycycline might affect aortic wall MMP
production in a larger series. This may not be feasi-
ble outside a prospective controlled trial in patients
with a small AAA, but one of the promising direc-
tions for future investigation is suggested by recent
evidence that circulating levels of MMP-9 are
increased in patients with an AAA.26 Thus, it will be
interesting to determine whether prolonged treat-
ment with doxycycline can influence serial measures
of plasma MMP-9, as a surrogate marker of enzyme
production within the aneurysm wall itself.
Finally, two technical limitations of this study were
related to the difficulty in measuring MMP enzymatic
activities in protein extracts from human AAA tissue by
means of in vitro assays and the apparent discrepancy
between results obtained by means of substrate
zymography and other techniques. Although in vitro
activity assays would have been useful in demonstrat-
ing whether doxycycline treatment has a direct influ-
ence on tissue MMP activity, we have found that accu-
rate measures of MMP activity in protein extracts from
AAA tissue are complicated by the co-extraction of
excess TIMP-1, a naturally occurring MMP inhibitor
that is overexpressed in human AAAs (Liao and
Thompson, unpublished observations).12,16,18,19 A
second concern was raised by the apparent lack of
effect of doxycycline treatment as determined by
means of gelatin zymography. Although zymography
is usually a sensitive technique for the detection of pro-
teinase activities, it is often quite insensitive as a mea-
sure of the activity present in different samples. We
found that resolution of gelatinase activities in AAA
extracts required a 10-fold reduction in the amount of
total protein loaded per lane, as compared with
immunoblots, and that inverse densitometry was an
insufficient means of measuring the 2.5-fold difference
in MMP-9 that we observed with immunoblot analy-
sis. We believe the results obtained by means of
immunoblotting are a more accurate reflection of the
events that occur in the aortic wall tissue of patients
treated with doxycycline, because this approach is sub-
ject to fewer variables than zymography and because
the quantitative results of immunoblotting were in
accord with those obtained by means of RNA analysis.
In contrast to the use of densitometric analysis as a
means of estimating total MMP activity, this approach
was more accurate in comparing the fractional activa-
tion of each enzyme because it was based on an inter-
nal control calculated for each enzyme in each sample.
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A consistent reduction in the activated fraction of
MMP-2 after doxycycline treatment, but no effect on
the activation of MMP-9, was revealed by means of
analysis of data obtained in four different experiments.
Although the difference in fractional activation of
MMP-2 was statistically significant between groups,
the overall effect was still only a slight reduction, com-
pared with that of untreated control patients. Because
active MMP-2 binds with high avidity to the extracel-
lular matrix in AAA tissue, a greater difference might
have been obtained with harsher tissue extraction con-
ditions.70 Further studies will, therefore, be needed to
clarify how doxycycline influences aortic wall MMP
activities detected by means of substrate zymography.
In summary, the present study establishes that
treatment with doxycycline is associated with signif-
icant inhibitory effects on the local expression and
post-translational processing (activation) of two
MMPs considered to be important in the pathogen-
esis and progression of human aortic aneurysms.
With the findings of previous studies, these findings
indicate that treatment with doxycycline may be a
useful approach to begin prospective clinical trials
aimed at reducing aneurysm expansion in patients
with small asymptomatic AAAs.
We thank Drs Lorne M. Golub (SUNY at Stoney
Brook) and William C. Parks (Washington University) for
helpful discussions and critical review of the manuscript.
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Dr William H. Pearce (Chicago, Ill). Dr Curci should
be commended for his excellent presentation. Before I make
my comments, I would like to point out that Drs Thompson
and Reilly are recipients of the Lifeline Foundation Award,
and it is clear that their basic science research has been
brought to human trials at this point. 
This paper is an excellent example of translational
research. A number of investigators, beginning with
Busuttil, have made observations that collagenolytic activity
is present in aortic aneurysm walls. Today, we know that
those enzymes are members of the metalloproteinase fami-
lies and, in particular, MMP-2 and MMP-9. Dr Thompson,
Dr Sicard and his colleagues, and Dr Reilly have pursued
this in an animal model and found that doxycycline inhibit-
ed aneurysm growth. It was only logical then that they
move from the bench to the bedside and try this in humans.
And, in fact, they used 100 mg twice a day and demon-
strated marked reductions in enzyme levels in the arterial
wall. What is interesting to me is that the large aneurysms
formed their control group. And from studies in our own
laboratory by Bill McMillan, these large aneurysm groups
have been found to have the lowest levels to begin with, so
their findings are even more dramatic. 
The studies that they have performed are well-designed,
and the techniques are impeccable. I have several questions
for the authors, only as a matter of discussion. 
First, in addition to the two matrix metalloproteinases
studied, MMP-2 and MMP-9, have you studied others? I
note that you have recent publications about MMP-12
and MMP-13. This is a very large family, and presumably
doxycycline will affect many of these enzymes. 
Second, have you studied any patients in a longitudi-
nal fashion? To prove the hypothesis, the reduction of
aneurysm growth or a marker such as serum MMP-9
should decline.
Finally, we know from studies in patients with rheuma-
toid arthritis that doxycycline or one of the modified
doxycyclines has been very effective in the treatment of
rheumatoid arthritis. Do you anticipate any problems with
long-term doxycycline treatment when we begin clinical
trials in patients with small aneurysms? 
I believe this paper is a model for translational research,
and I compliment the St. Louis group on their persistence
in bringing this to us today. And I’d like to thank the
Society for the privilege of discussing this paper. Thank you.
Dr Robert W. Thompson. Thank you very much, Dr
Pearce. 
The first question you asked was about whether we have
studied other matrix metalloproteinases. Today, we’ve only
looked at MMP-2 and MMP-9 in detail. We do have a great
interest in MMP-12, macrophage elastase, which is also
markedly elevated in aneurysm tissue, but we have not yet
done detailed studies in human tissue on the effect of doxy-
cycline treatment on MMP-12. We will continue to extend
this to other matrix metalloproteinases in the family that
may be involved in aneurysm disease in the next year. 
To answer your second question regarding longitudinal
follow-up, that really is the prelude to a longer-term clinical
trial. We have shown now that we can, in even 1 week of
treatment, affect matrix metalloproteinase activity and pro-
duction in human aneurysm tissue. This is an important first
step, but it is, in a sense, preliminary data. What we really
DISCUSSION
need to do now is show that by affecting matrix metallopro-
teinase activity in human aneurysm tissue we can actually
influence the natural history of a small aortic aneurysm. This
will require a large randomized clinical trial. We are current-
ly in the process of organizing and beginning such a trial. Dr
Timothy Baxter at the University of Nebraska and myself,
with physicians from several other centers in the Midwest,
have started a pilot phase study, and we hope to be entering
a larger-scale study within approximately 6 to 9 months. This
will naturally take approximately 4 or 5 years of follow-up, I
think, before we’ll have an answer. But this is the critical
question, and we don’t know yet if any form of pharma-
cotherapy will affect the natural history of small aortic
aneurysms. 
Doxycycline and even low-dose doxycycline in another
chemical formulation have been used as matrix metallopro-
teinase inhibitors in clinical trials for other conditions, such
as rheumatoid arthritis. Osteoarthritis of the knee is also
being studied in a large-scale clinical trial with doxycycline.
And periodontal disease, in which the use of tetracyclines
really began as matrix metalloproteinase inhibitors, has also
been studied for the last 13 years. In these situations, doxy-
cycline has been used successfully as an matrix metallopro-
teinase inhibitor, and there have not been major problems
with adverse effects of the antibiotic. There are some drug-
specific adverse effects, such as photosensitivity, and there are
some incidents of gastrointestinal disturbance with doxycy-
cline, but these have been relatively minor. Particularly in the
trials of rheumatoid arthritis and osteoarthritis, the patient
populations are in many ways similar to the group of patients
we would be proposing to treat with aneurysms, so I think
that this is a promising route by which we can begin to test
this hypothesis. 
Thanks once again.
Dr David R. Jackson (Northhampton, Mass). This is
a very intriguing and interesting paper. Many of us in this
audience treat chronic, nonhealing diabetic and nondia-
betic foot ulcers. Recent wound healing research has
shown that the metalloproteinase MMP-9 is highly preva-
lent in many of these chronic wounds. Some of the
researchers have indicated that they think that the effect
on the collagenases in the wound to decrease the effect on
the collagen matrix formation may be part of the reason
why these chronic wounds don’t heal. I wonder if the
authors have any information about whether doxycycline
has been used in the treatment of chronic foot ulcers?
Dr Alexander W. Clowes (Seattle, Wash). I want to
commend the authors on a very interesting study and
underscore an important new development, a set of surro-
gate endpoints to test out their pharmacology first before
going for the final long-range endpoint. I think this is a
very important principle. 
I would like to ask about carotid disease, another dis-
ease that involves disruption of the wall, but is limited to
the intima. One would suppose that giving some form of
tetracycline/doxycycline might suppress the disruption of
the fibrous cap, and one would have the opportunity also
to determine whether the drug could affect the proteases
that are involved in this process. Have you had a look at
carotid endarterectomy specimens to see whether you can
see the same kind of effect of doxycycline on the proteas-
es in those lesions?
Dr Joseph M. Van De Water (Macon, Ga). Is there an
application of this research to other conditions in which
you have degradation of elastin, such as bronchiectasis or
maybe even the common hernia?
Dr Thompson. Thank you for your questions. 
Dr Jackson asked about wound healing and the use of
doxycycline as an matrix metalloproteinase inhibitor.
Matrix metalloproteinases, not only MMP-2 and MMP-9
but many others, particularly collagenases, are clearly
involved in wound healing. Doxycycline and other tetra-
cyclines are broad spectrum matrix metalloproteinase
inhibitors. By means of the mechanism by which they are
direct antagonists, they can affect all members of the
matrix metalloproteinase class. We don’t have any specific
data on wound healing, but these enzymes are being stud-
ied in great detail by others. 
Dr Clowes asked about the carotid plaque, and I think
that this is a very intriguing problem that parallels
aneurysm disease. Metalloproteinases are clearly involved
in the breakdown of matrix in the fibrous cap of athero-
sclerotic plaques, wherever they are, and can lead to
plaque vulnerability, rupture, and clinical complications.
Clearly, an matrix metalloproteinase inhibitor may be a
promising clinical therapeutic approach for this problem.
We have done no studies on carotid lesions in particular;
but a parallel study, of the nature we presented today,
would be very intriguing and promising. 
Finally, we have done no studies on hernia or other
specific conditions related to elastin, but any of the matrix
metalloproteinases that break down elastin—there are four
in the family that do so—can be inhibited by tetracycline
or other members of this class. So, although we have no
data, this would be another promising area for future
research. 
I thank the Society, once again, for the opportunity to
present.
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